Eli Lilly halves $2.5 billion Alzey investment

Eli Lilly will finish only the "minimum scope" of its $2.5 billion factory in Alzey, Germany. The shell of the plant is nearly complete and 300 workers have already been hired, but the promised move towards 1,000 jobs is gone. Within hours, Boehringer Ingelheim cancelled €900 million in planned German investment for 2027-2030. Both companies gave the same reason: Berlin's new law to cut health-insurance costs.

Berlin's fiscal corner

The law, the GKV-Beitragssatzstabilisierungsgesetz, or health insurance contribution stabilisation act, comes from a real squeeze. Germany's average health insurance contribution reached a record 17.5% of gross wages in 2026. The country's council of economic advisers projects that total social contributions could reach 49.7% by 2040 without reform. The law is meant to find €16.3 billion in savings across the health system by 2027.

For pharma, the lever that matters is a "dynamic manufacturer rebate", a mandatory discount on drug prices that rises automatically as insurance spending grows. Industry groups disagree sharply on where it could end up. The vfa, Germany's main pharma lobby, puts it at roughly 20% of list prices by 2030. Pharma Deutschland, which represents generic and mid-sized drugmakers, warns it could reach 50%. Companies say the problem is less today's rebate than the built-in escalation, which makes long-term investment planning harder. Pharma accounts for about 3.3% of health insurance spending but carries roughly 12% of the planned savings.

Paris has the cheque book ready

Boehringer's turn towards France was not a stray decision. On June 1, the company pledged €500 million across four French production sites at Emmanuel Macron's "Choose France" investment summit. Two days later came the €900 million cancellation in Germany. Total pharma investment announced at Choose France reached €600 million, three times the previous year's figure.

The wider pattern is awkward for Berlin. According to the EY attractiveness barometer, foreign investment projects in Germany have fallen 44% since 2019, while France's decline was 28%. Boehringer's Germany chief put it plainly: "The next innovation will, as things stand, not go to Germany".

84% margins against mandatory rebates

Eli Lilly is not a company pleading poverty. It posted revenue of $65.2 billion in 2025, up 45% in a single year, with gross margins of 84.3%. In plain terms, 84 cents of every dollar in revenue survived production costs. Boehringer reported €27.8 billion in revenue, up 7.3%. German prices for patented drugs already sit at 114% of the European average. At those margins and price levels, the claim that higher German rebates are commercially unbearable is hard to square with the accounts.

The episode also shows where Brussels runs out of road. The EU reached a provisional deal on its Critical Medicines Act in May 2026, designed to bring pharmaceutical production back to Europe. But health-care pricing remains a national competence under the EU treaties. Each government sets its own drug prices, and Brussels cannot overrule them. The EU can encourage companies to build factories in Europe. It cannot stop a member state from weakening its own investment pitch.

Europe's share of global API production has fallen from 63% in 1981 to roughly 6% today. API means active pharmaceutical ingredient, the chemical compound that makes a drug work. The Critical Medicines Act's proposed €5 billion fund is still a line in a future EU budget, not committed money.

That leaves Berlin in a hard place. It has to contain health costs that are squeezing workers and employers already paying record contributions. But if investment goes to Toulouse and Cork rather than Alzey and Ingelheim, Europe's pharmaceutical sovereignty is being thinned out from within. The immediate pressure is not Beijing. It is the fiscal emergency inside member states themselves.